Fidelis Capital Partners LLC Makes New $46,000 Investment in Royalty Pharma plc (NASDAQ:RPRX)

Fidelis Capital Partners LLC purchased a new position in Royalty Pharma plc (NASDAQ:RPRXFree Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 1,518 shares of the biopharmaceutical company’s stock, valued at approximately $46,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Tokio Marine Asset Management Co. Ltd. lifted its position in shares of Royalty Pharma by 10.8% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 9,097 shares of the biopharmaceutical company’s stock worth $276,000 after buying an additional 887 shares during the last quarter. Capstone Investment Advisors LLC acquired a new stake in shares of Royalty Pharma in the first quarter worth about $542,000. Allspring Global Investments Holdings LLC lifted its position in shares of Royalty Pharma by 4,335.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 2,750 shares of the biopharmaceutical company’s stock worth $84,000 after buying an additional 2,688 shares during the last quarter. Principal Financial Group Inc. lifted its position in shares of Royalty Pharma by 34.6% in the first quarter. Principal Financial Group Inc. now owns 31,485 shares of the biopharmaceutical company’s stock worth $956,000 after buying an additional 8,086 shares during the last quarter. Finally, Phillips Wealth Planners LLC acquired a new stake in shares of Royalty Pharma in the first quarter worth about $241,000. Institutional investors and hedge funds own 54.35% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on RPRX. StockNews.com lowered Royalty Pharma from a “buy” rating to a “hold” rating in a research note on Friday, May 10th. UBS Group lowered Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price objective on the stock. in a research note on Monday, June 3rd. Finally, Bank of America dropped their price objective on Royalty Pharma from $40.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday, April 12th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $43.00.

Get Our Latest Report on RPRX

Royalty Pharma Stock Down 0.3 %

Shares of RPRX opened at $25.63 on Wednesday. The company has a market capitalization of $15.31 billion, a P/E ratio of 19.13, a PEG ratio of 3.36 and a beta of 0.46. The company has a debt-to-equity ratio of 0.62, a current ratio of 12.52 and a quick ratio of 12.52. Royalty Pharma plc has a one year low of $25.20 and a one year high of $31.66. The business’s 50 day simple moving average is $27.07 and its 200-day simple moving average is $28.41.

Royalty Pharma (NASDAQ:RPRXGet Free Report) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.96 by $0.02. The business had revenue of $568.00 million for the quarter, compared to the consensus estimate of $671.45 million. Royalty Pharma had a return on equity of 22.94% and a net margin of 35.70%. During the same period in the previous year, the business earned $1.60 EPS. As a group, sell-side analysts predict that Royalty Pharma plc will post 4.03 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 14th. Stockholders of record on Friday, May 17th were issued a $0.21 dividend. This represents a $0.84 annualized dividend and a dividend yield of 3.28%. The ex-dividend date was Thursday, May 16th. Royalty Pharma’s payout ratio is currently 62.69%.

About Royalty Pharma

(Free Report)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

Featured Stories

Institutional Ownership by Quarter for Royalty Pharma (NASDAQ:RPRX)

Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.